Drugs /

rifampin

Back to Drugs List

Overview

NCI Definition [1]:
A semisynthetic derivative of rifamycin with broad antibacterial activity. Rifampin inhibits DNA-dependent RNA polymerase in susceptible bacteria and is often used in combination with other antibiotics for various infections including tuberculosis.

Clinical Trials

View Clinical Trials for rifampin

Rifampin has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating rifampin, 4 are phase 1 (3 open).

ALK Alternative Transcription Site, ALK Amplification, and ALK Expression are the most frequent biomarker inclusion criteria for rifampin clinical trials.

Cancer, malignant solid tumor, and solid neoplasm are the most common diseases being investigated in rifampin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Rifampin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Rifampin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rifampin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
rimactane, rifadin, l-5103
NCIT ID [1]:
C811

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.